Welcome to our dedicated page for Benitec Biopharm SEC filings (Ticker: BNTC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Benitec Biopharma Inc. (NASDAQ: BNTC) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage, gene therapy-focused biotechnology company, Benitec uses its SEC reports to outline progress on its Silence and Replace DNA-directed RNA interference (ddRNAi) platform, the clinical development of its lead candidate BB-301 for Oculopharyngeal Muscular Dystrophy (OPMD)-related dysphagia, and its financial position.
Key filings include annual reports on Form 10‑K, which summarize full-year financial results, research and development expenses related primarily to BB-301, and broader operational updates. Quarterly reports on Form 10‑Q provide interim financial statements, cash and cash equivalents balances, and management’s discussion of ongoing clinical and corporate activities. These documents allow readers to track how Benitec funds and advances its Silence and Replace-based therapeutics over time.
Benitec also files current reports on Form 8‑K to announce material events. Recent 8‑K filings have covered topics such as positive interim clinical results from the BB-301 Phase 1b/2a trial, the FDA’s Fast Track Designation for BB-301, equity financings through underwritten and registered direct offerings, and board appointments. The company’s Definitive Proxy Statement on Schedule 14A discloses information on governance, director elections, executive compensation, equity incentive plans, and the annual meeting of stockholders.
On Stock Titan, these filings are complemented by AI-powered summaries that highlight important points from lengthy documents, such as clinical development updates, changes in cash runway, or terms of financing transactions. Users can quickly review 10‑K and 10‑Q reports with AI-generated insights, and scan Form 8‑K items for material agreements, capital raises, and regulatory news. Where applicable, Form 4 insider transaction reports can also be monitored to see how directors and officers transact in BNTC shares.
For investors analyzing Benitec’s gene therapy pipeline and financial condition, this SEC filings page offers a structured view of real-time EDGAR updates, summarized by AI, making it easier to understand the implications of complex regulatory documents without reading every line of each filing.
Benitec Biopharma reported its second fiscal quarter ended December 31, 2025, highlighting both financial results and progress for BB-301, its gene therapy for Oculopharyngeal Muscular Dystrophy-related dysphagia. Total expenses were $13.4 million, up from $10.8 million a year earlier, driven mainly by higher general and administrative costs. Net loss attributable to shareholders was $11.8 million, or $(0.26) per share, compared with a net loss of $9.6 million, also $(0.26) per share, in the prior-year quarter. The company held $189 million in cash and cash equivalents as of December 31, 2025, providing substantial funding for its clinical programs.
Clinically, all four patients in Cohort 1 of the BB-301 Phase 1b/2a study were classified as responders at 12 months using a predefined Responder Analysis, indicating durable benefit. One patient maintained and deepened improvements in swallowing measures and symptom burden at 24 months post-treatment. Enrollment in Cohort 2 at a higher BB-301 dose is ongoing, with an interim update planned for mid-2026. BB-301 has Orphan Drug and Fast Track designations, and the company plans an FDA meeting in mid-2026 to confirm the pivotal study design.
Benitec Biopharma Inc. reported another quarter as a clinical-stage biotech with no product revenue and continued investment in its genetic medicine platform. For the six months ended December 31, 2025, the company recorded a net loss of $20.8 million, compared with $14.6 million a year earlier, driven by higher research and development spending of $9.2 million and general and administrative expenses of $14.0 million.
Benitec significantly strengthened its balance sheet, ending the period with $188.8 million in cash and cash equivalents, up from $97.7 million at June 30, 2025, primarily from equity offerings that generated gross proceeds of about $104.5 million. Total assets were $190.7 million and stockholders’ equity was $187.4 million. Management states this cash should fund operations for at least the next twelve months as the company advances its lead OPMD gene therapy candidate BB-301 through an ongoing Phase 1b/2a program. Shares outstanding were 34,254,907 at December 31, 2025 and 34,354,334 as of February 6, 2026.
Benitec Biopharma Inc. is registering 1,481,481 shares of common stock for resale by entities affiliated with Suvretta Capital that bought these shares in a November 2025 registered direct offering. Benitec will not receive any proceeds from these secondary sales but will cover registration expenses.
The resale follows concurrent November 2025 offerings in which Benitec sold 5,930,000 shares in an underwritten deal and 1,481,481 shares in the registered direct deal at $13.50 per share, plus an additional 328,889 shares later, for aggregate gross proceeds of about $100 million. The company is a clinical-stage biotech developing BB-301, a “silence and replace” gene therapy candidate for Oculopharyngeal Muscular Dystrophy, using its DNA-directed RNA interference platform.
Entities affiliated with Suvretta Capital beneficially owned 17,952,309 shares of common stock as of February 10, 2026 and, assuming full resale of the registered shares, would beneficially own 16,470,828 shares, representing 40.9% of Benitec’s common stock.
Benitec Biopharma Inc. has filed a resale registration statement covering 1,481,481 shares of common stock held by existing investors from a prior registered direct offering. The company is registering these shares to satisfy a Registration Rights Agreement tied to a November 7, 2025 financing.
Benitec will not receive any proceeds from sales under this prospectus, though it will cover registration expenses. The shares are owned by entities affiliated with Suvretta Capital Management, which beneficially held 17,952,309 shares as of January 26, 2026, representing a significant ownership stake. The filing highlights risks from concentrated ownership, potential warrant exercises, and resale-related stock price pressure.
Franklin Resources and affiliates have reported a significant ownership position in Benitec Biopharma Inc. They report beneficial ownership of 3,751,709 shares of common stock, representing 10.6% of the company as of 12/31/2025, including 1,554,404 shares issuable upon exercise of warrants.
Franklin Advisers, Inc. holds sole voting and dispositive power over these 3,751,709 shares. Charles B. Johnson and Rupert H. Johnson, Jr. are listed as reporting persons but show no directly beneficially owned shares. A key client, Franklin Biotechnology Discovery Fund, has an interest in 2,445,585 shares, or 6.9% of the class.
The securities are held for investment management clients in the ordinary course of business, and the filers state they were not acquired to change or influence control of Benitec. Franklin Resources, the principal shareholders, and subsidiaries also disclaim being a group or ultimate beneficial owners beyond their investment management role.
Benitec Biopharma Inc. director Sharon Mates received a grant of stock options covering 31,500 shares of common stock. The options were awarded on January 22, 2026 at an exercise price of
These options are held directly and give the right to buy Benitec common stock in the future. According to the terms, the options will vest on the earlier of the company’s next annual stockholders’ meeting or
Benitec Biopharma Inc. (BNTC) reported a new stock option grant to its Chief Operating Officer, Sophie Mukadam, in an ownership filing. On 11/18/2025, she received options to purchase 500,000 shares of Benitec common stock at an exercise price of $13.53 per share, expiring on 11/18/2035. These options are scheduled to vest in 16 substantially equal quarterly installments beginning on March 31, 2026, meaning the award vests gradually over four years while she remains in her role.
Benitec Biopharma Inc. (BNTC) reported an equity award to its Chief Executive Officer and director, Jerel A. Banks, on a Form 4. On November 18, 2025, he received 450,000 stock options with an exercise price of $13.53 per share, giving him the right to buy Benitec common stock at that price.
The options have a long-term horizon, expiring on November 18, 2035. According to the filing, they will vest in 16 substantially equal quarterly installments, beginning on March 31, 2026. After this grant, Jerel A. Banks beneficially owned 450,000 stock options, held directly.
Benitec Biopharma Inc. (BNTC) reported a stock option grant to director and Chief Financial Officer Megan Boston. On 11/18/2025, she received options to purchase 200,000 shares of common stock at an exercise price of $13.53 per share, expiring on 11/18/2035.
The options will vest in 16 substantially equal quarterly installments beginning on March 31, 2026, meaning the award vests gradually over four years. The filing indicates she holds these options directly, reflecting a standard equity-based compensation grant that aligns executive incentives with shareholder interests.
Benitec Biopharma Inc. (BNTC) filed an 8‑K stating it furnished a press release with financial results for the fiscal quarter ended September 30, 2025, and an operational update. The press release is attached as Exhibit 99.1.
The company notes the information furnished under Item 2.02, including Exhibit 99.1, is not deemed filed for liability purposes and is not incorporated by reference unless expressly stated. BNTC’s common stock trades on The Nasdaq Stock Market LLC.